In a non-randomised phase I/II trial (NCT04180371), the BT5528 drug (bicycle peptide targeting EphA2) is being used in combination with nivolumab for the treatment of advanced solid tumours including pancreatic cancer. This evidence concerns the gene EPHA2 and pancreatic neoplasm.